USFDA closes Dr. Reddy's Bachupally FTO-3 inspection with Voluntary Action Indicated status
Dr. Reddy's says the US regulator has classified its Hyderabad formulations plant inspection as VAI and considers the inspection officially closed.
Dr. Reddy's Laboratories has told Indian and US stock exchanges that the US Food and Drug Administration classified the GMP inspection of its FTO-3 formulations facility in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI). The company made the disclosure on 14 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Dr Reddys Laboratories Ltd ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.